The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Ascentage Pharma’s four assets selected for 68th ASH Annual Meeting

Nov 5, 2026 00:35 (7h ago)

Verifying

Ascentage Pharma announced research-program selections for the 68th ASH Annual Meeting.
Four covered assets are olverembatinib, lisaftoclax, APG-5918 and APG-328.
Ascentage Pharma issued the voluntary announcement on November 5.